Compound information
- Natural Products
- NACP151227
- Molecular Formula
- C18H30O4
- Molecular Weight
- 310.21440944 g/mol
- Structure
-
- IUPAC Name
- 9,12-dioxooctadec-10-enoic acid
- InChI
- InChI=1S/C18H30O4/c1-2-3-4-8-11-16(19)14-15-17(20)12-9-6-5-7-10-13-18(21)22/h14-15H,2-13H2,1H3,(H,21,22)
- InChI Key
- WYLMMQRVMQAKNJ-UHFFFAOYSA-N
- SMILES
- O=C(O)CCCCCCCC(=O)C=CC(=O)CCCCCC
- CAS
- 28833-56-9
- SuperClass
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- SubClass
- Lineolic acids and derivatives
- Source
- CNP0341381
Warheads
- Michael Acceptor
-
- Michael Acceptor
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 22 | Ring Count | 0 |
| Heteroatom Count | 4 | Rotatable Bond Count | 15 |
| Hydrogen Bond Acceptor Count | 3 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 71.44 Å2 | LogP | 4.175 |
| LogS | -3.727 | LogD | 2.62 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.263 | Pgp substrate | 0.002 |
| HIA | 0.967 | F20 % | 0.854 |
| F30 % | 0.006 | Caco-2 | -4.874 |
| MDCK | -4.56 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.914 | PPB | 85.646 |
| VD | 0.689 | Fu | 1.75 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.208 | CYP1A2 substrate | 0.261 |
| CYP2A6 substrate | 0.336 | CYP2B6 substrate | 0.485 |
| CYP2C19 inhibitor | 0.043 | CYP2C19 substrate | 0.295 |
| CYP2C8 substrate | 0.566 | CYP2C9 inhibitor | 0.187 |
| CYP2C9 substrate | 0.021 | CYP2D6 inhibitor | 0.065 |
| CYP2D6 substrate | 0.099 | CYP2E1 substrate | 0.334 |
| CYP3A4 inhibitor | 0.075 | CYP3A4 substrate | 0.023 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.829 | CL | 2.272 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.295 | Hepatotoxicity | 0.799 |
| Mutagenicity | 0.232 | Rat Oral Acute Toxicity | 0.032 |
| FDAMDD | 0.469 | Skin Sensitization | 0.992 |
| Carcinogenicity | 0.744 | Eye Corrosion | 0.195 |
| Eye Irritation | 0.943 | Respiratory Toxicity | 0.303 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 0.448 | IGC50 | 4.704 |
| LC50FM | 4.804 | LC50DM | 5.571 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.332 | NR-AR-LBD | 0.278 |
| NR-AhR | 0.004 | NR-Aromatase | 0.111 |
| NR-ER | 0.283 | NR-ER-LBD | 0.362 |
| NR-PPAR-gamma | 0.856 | SR-ARE | 0.199 |
| SR-ATAD5 | 0.31 | SR-HSE | 0.184 |
| SR-MMP | 0.027 | SR-p53 | 0.115 |
Similar covalent inhibitors
Similar covalent drugs
No similar covalent drugs found for this compound.